Na Ho-Jeong, Shin Hye-Young, Kim Na-Hyung, Kwon Mi-Won, Park Eun-Jeong, Hong Seung-Heon, Kim Nam-Il, Kim Hyung-Min
College of Oriental Medicine, Kyung Hee University, Dongdaemun-Gu, Seoul, South Korea.
Inflammation. 2004 Oct;28(5):291-8. doi: 10.1007/s10753-004-6053-0.
Gammi-danguieumja (GD) is clinically used in South Korea for treating atopic dermatitis. However, its effects in experimental models remain unknown. We investigated a possible effect of GD on cytokines production using human T cell line (MOLT-4) or human mast cell line. As a result, GD (0.01 mg/mL)-containing medium in stimulated culture supernatants increased IL-2 and IFN-gamma, and decreased IL-4 secretion in MOLT-4. GD (0.01-1 mg/mL)-containing medium in stimulated culture supernatants dose-dependently and significantly decreased IL-8, IL-13, and tumor necrosis factor-alpha secretion on the phorbol 12-myristate 13-acetate and A23187-stimulated HMC-1. In addition, GD inhibited histamine release from activated mast cells. These results suggest that GD contributes to the regulation of atopic allergic reactions.
加味当归芍药散(GD)在韩国临床上用于治疗特应性皮炎。然而,其在实验模型中的作用尚不清楚。我们使用人T细胞系(MOLT-4)或人肥大细胞系研究了GD对细胞因子产生的可能影响。结果,在刺激的培养上清液中含GD(0.01 mg/mL)的培养基增加了IL-2和IFN-γ,并减少了MOLT-4中IL-4的分泌。在刺激的培养上清液中含GD(0.01 - 1 mg/mL)的培养基在佛波醇12-肉豆蔻酸酯13-乙酸酯和A23187刺激的HMC-1上剂量依赖性且显著地减少了IL-8、IL-13和肿瘤坏死因子-α的分泌。此外,GD抑制了活化肥大细胞中组胺的释放。这些结果表明GD有助于调节特应性过敏反应。